Orthocell was featured in the widely read column, Dr Boreham’s Crucible, written by respected small cap analyst and business journalist, Tim Boreham.Â
Stockhead Investor Guide | September 2022
Orthocell was featured in the widely read column, Dr Boreham’s Crucible, written by respected small cap analyst and business journalist, Tim Boreham.Â
Ortho-ATIâ„¢ Shoulder Tendon Study Update
Orthocell has today shared positive results from the crossover extension arm of our randomised clinical trial examining the performance of our OrthoATIâ„¢ therapy in the treatment of rotator cuff tendon injuries, compared to a steroid injection.
First orders for dental and nerve productsÂ
Orthocell has now received first purchase orders for our flagship collagen medical device products Striate+â„¢ and Remplir, via our valued distribution partners.
Beyond the Medicine Cabinet Podcast | September 2022
Orthocell’s CEO and Managing Director Paul Anderson has featured on Beyond The Medicine Cabinet podcast to talk about regenerative nerve repair, and how Orthocell’s Remplir™ collagen nerve wrap is revolutionising surgery for patients with peripheral nerve injuries.
VIDEO | Proactive Investors – September 2022
Orthocell’s Paul Anderson spoke with Andrew Scott at Proactive Investors to discuss to discuss the announcement that the Company had secured Device Technologies as the exclusive distribution partner for Remplirâ„¢ in the Australian marketplace.Â
Orthocell appoints Device Technologies as distributor of its nerve repair device in Aus, NZ
Orthocell’s distribution deal with Device Technologies has been featured in The West Australian, in this news article by business reporter Cheyanne Enciso.
Appointment of exclusive distributor of Remplirâ„¢ in Australia
Orthocell has appointed Device Technologies as the exclusive distributor of Remplirâ„¢ for peripheral nerve repair in Australia.Â
VIDEO | Proactive Investors – July 2022
Orthocell’s Paul Anderson spoke with Alisha Newell at Proactive Investors to discuss the Company’s strong position following the recently executed global exclusive licence and distribution agreement with BioHorizons Implant Systems Inc for $OCC’s Striate+™ dental membrane.
Dr Boreham’s Crucible | July 2022
Orthocell was featured in the widely read column, Dr Boreham’s Crucible, written by respected small cap analyst and business journalist, Tim Boreham.Â